Search

REVOLUTION Medicines Inc

Avatud

SektorTervishoid

210.64 -0.4

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

208.24

Max

215.55

Põhinäitajad

By Trading Economics

Sissetulek

-644M

-1.1B

Aktsiakasum

-2.34

Töötajad

883

EBITDA

-184M

-621M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+5.35% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

6.7B

45B

Eelmine avamishind

211.04

Eelmine sulgemishind

210.64

Uudiste sentiment

By Acuity

83%

17%

320 / 340 Pingereas Healthcare

REVOLUTION Medicines Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21. aug 2026, 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20. aug 2026, 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19. aug 2026, 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17. aug 2026, 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13. aug 2026, 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12. aug 2026, 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11. aug 2026, 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10. aug 2026, 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7. aug 2026, 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6. aug 2026, 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5. aug 2026, 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4. aug 2026, 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3. aug 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31. juuli 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30. juuli 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29. juuli 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28. juuli 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27. juuli 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24. juuli 2026, 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22. juuli 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21. juuli 2026, 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20. juuli 2026, 17:31 UTC

Social Media
News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Võrdlus sarnastega

Hinnamuutus

REVOLUTION Medicines Inc Prognoos

Hinnasiht

By TipRanks

5.35% tõus

12 kuu keskmine prognoos

Keskmine 222.89 USD  5.35%

Kõrge 291 USD

Madal 179 USD

Põhineb 19 Wall Streeti analüütiku instrumendi REVOLUTION Medicines Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

18

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

320 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat